Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Fountain Acquisition Corp. was a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. While the company was sector-agnostic, its management team and board of directors had significant experience in the healthcare, consumer-facing technology, and wellness sectors, often targeting companies within these industries. The company was led by CEO Jonathan J. Ledecky and was listed on the Nasdaq under the symbol FACU. Ultimately, the company did not complete a business combination within its allotted timeframe and proceeded to liquidate its assets and redeem its public shares.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Fountain Acquisition.